Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: August 31, 2005
Last updated: June 1, 2007
Last verified: June 2007
Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.

Condition Intervention Phase
Smoking Cessation
Drug: varenicline (CP-526,555)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter Study With Follow-Up Evaluating the Safety and Efficacy of Varenicline Tartrate in Comparison to Transdermal Nicotine Patch for Smoking Cessation

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Continuous abstinence for the last 4 weeks of varenicline and NRT (Nicotine Replacement Therapy) treatment period

Secondary Outcome Measures:
  • Continuous abstinence last 4 weeks of treatment through Weeks 24 and 52
  • 7-day point prevalence of abstinence: end of treatment, Weeks 24 and 52
  • 4-week Point Prevalence of abstinence at Week 52
  • Long-Term Quit Rate at Weeks 24 and 52
  • Minnesota Nicotine Withdrawal Scale
  • Smoking Effects Inventory

Estimated Enrollment: 730
Study Start Date: January 2005
Study Completion Date: June 2006

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have smoked an average of at least 15 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion Criteria:

  • Subjects with clinically significant cardiovascular disease in the past 6 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00143325

United States, California
Pfizer Investigational Site
Palo Alto, California, United States
Pfizer Investigational Site
Santa Ana, California, United States
United States, Connecticut
Pfizer Investigational Site
Farmington, Connecticut, United States
United States, Kentucky
Pfizer Investigational Site
Lexington, Kentucky, United States
United States, Massachusetts
Pfizer Investigational Site
Worcester, Massachusetts, United States
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Bruxelles, Belgium
Pfizer Investigational Site
Edegem, Belgium
Pfizer Investigational Site
Gent, Belgium
Pfizer Investigational Site
Caen, France
Pfizer Investigational Site
Clermont-Ferrand, France
Pfizer Investigational Site
Limeil Brevannes, France
Pfizer Investigational Site
Limeil-Brevannes, France
Pfizer Investigational Site
Metz CEDEX 01, France
Pfizer Investigational Site
Metz Cedex 1, France
Pfizer Investigational Site
Paris, France
Pfizer Investigational Site
Vandoeuvre les Nancy, France
Pfizer Investigational Site
Amsterdam, Netherlands
Pfizer Investigational Site
Enschede, Netherlands
Pfizer Investigational Site
Maastricht, Netherlands
Pfizer Investigational Site
Zutphen, Netherlands
United Kingdom
Pfizer Investigational Site
London, Surrey, United Kingdom
Pfizer Investigational Site
London, United Kingdom
Pfizer Investigational Site
Nottingham, United Kingdom
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00143325     History of Changes
Other Study ID Numbers: A3051044
Study First Received: August 31, 2005
Last Updated: June 1, 2007

Additional relevant MeSH terms:
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on April 21, 2017